Vestibular neuritis (VN) is characterized by acute vertigo with spontaneous nystagmus and is often accompanied by vegetative symptoms. While the pathogenetic process leading to this disease is widely unknown, increasing evidence exists that a proinflammatory environment is responsible for the induction and progression of VN. Twelve patients with acute VN and 12 healthy, age-matched individuals were included in this study. In addition to routine blood parameters, plasma levels of soluble CD40 receptor/ligand (sCD40/sCD40L) were determined by ELISA. Moreover, peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density gradient. Afterwards, in CD14 (monocytes), CD68 (macrophages), CD3 (T lymphocytes) or CD19 (B lymphocytes) subpopulations, proinflammatory [CD40, tumor necrosis factor-α (TNF-α), and COX-2], proapoptotic [caspase-3, and poly(adenosine diphosphate ribose) polymerase] and proadhesive (CD38) proteins were measured by 2-color fluorescence-activated cell sorter analyses. In comparison to healthy individuals, patients with acute VN revealed significantly elevated plasma levels of C-reactive protein, whereas plasma levels of sCD40 and sCD40L, as well as cholesterol/triglyceride status were similar. However, we found a significant elevation of the percentage of proinflammatory CD40+, TNF-α+, COX-2+ or CD38+ PBMCs. Elevation of proinflammatory and proadhesive proteins in PBMCs of patients with acute VN in parallel with an acute phase response may contribute to disease induction and progression and, thus, may be suggested as a novel therapeutic target.

1.
Bartual-Pastor J: Vestibular neuritis: etiopathogenesis. Rev Laryngol Otol Rhinol (Bord) 2005;126:279–281.
2.
Bjorck P, Braesch-Andersen S, Paulie S: Antibodies to distinct epitopes on the CD40 molecule co-operate in stimulation and can be used for the detection of soluble CD40. Immunology 1994;83:430–437.
3.
Bonaterra GA, Hildebrandt W, Bodens A, Sauer R, Dugi KA, Deigner HP, Droge W, Metz J, Kinscherf R: Increased cyclooxygenase-2 expression in peripheral blood mononuclear cells of smokers and hyperlipidemic subjects. Free Radic Biol Med 2005;38:235–242.
4.
Bonaterra GA, Hildebrandt W, Bodens A, Sauer R, Dugi KA, Deigner HP, Turcanu D, Heinle H, Droge W, Metz J, Kinscherf R: Increased gene expression of scavenger receptors and proinflammatory markers in peripheral blood mononuclear cells of hyperlipidemic males. J Mol Med 2007;85:181–190.
5.
D’Amours D, Desnoyers S, D’Silva I, Poirier GG: Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999;342:249–268.
6.
Deaglio S, Morra M, Mallone R, Ausiello CM, Prager E, Garbarino G, Dianzani U, Stockinger H, Malavasi F: Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol 1998;160:395–402.
7.
Decker P, Isenberg D, Muller S: Inhibition of caspase-3-mediated poly(ADP-ribose) polymerase (PARP) apoptotic cleavage by human PARP autoantibodies and effect on cells undergoing apoptosis. J Biol Chem 2000;275:9043–9046.
8.
Fattori B, Ursino F, Cristofani R, Galetta F, Nacci A: Relevance of plasma D-dimer measurement in patients with acute peripheral vertigo. J Laryngol Otol 2003;117:467–472.
9.
Freedman JE, Loscalzo J: Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation 2002;105:2130–2132.
10.
Gaur U, Aggarwal BB: Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 2003;66:1403–1408.
11.
Guedes AG, Jude JA, Paulin J, Kita H, Lund FE, Kannan MS: Role of CD38 in TNF-alpha-induced airway hyperresponsiveness. Am J Physiol Lung Cell Mol Physiol 2008;294:L290–L299.
12.
Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591–594.
13.
Ishiyama A, Ishiyama GP, Lopez I, Eversole LR, Honrubia V, Baloh RW: Histopathology of idiopathic chronic recurrent vertigo. Laryngoscope 1996;106:1340–1346.
14.
Kassner SS, Bonaterra GA, Kaiser E, Hildebrandt W, Metz J, Schroder J, Kinscherf R: Novel systemic markers for patients with Alzheimer disease? – A pilot study. Curr Alzheimer Res 2008;5:358–366.
15.
Kassner S, Kollmar R, Bonaterra G, Hildebrandt W, Schwab S, Kinscherf R: The early immunological response to acute ischemic stroke: differential gene expression in subpopulations of mononuclear cells. Neuroscience 2009;160:394–401.
16.
Kitahara T, Kondoh K, Morihana T, Okumura S, Horii A, Takeda N, Kubo T: Steroid effects on vestibular compensation in human. Neurol Res 2003;25:287–291.
17.
Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, Chu K, McGarry TJ, Kirschner MW, Koths K, Kwiatkowski DJ, Williams LT: Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 1997;278:294–298.
18.
Koya RC, Fujita H, Shimizu S, Ohtsu M, Takimoto M, Tsujimoto Y, Kuzumaki N: Gelsolin inhibits apoptosis by blocking mitochondrial membrane potential loss and cytochrome c release. J Biol Chem 2000;275:15343–15349.
19.
Milionis HJ, Mittari V, Exarchakos G, Kalaitzidis R, Skevas AT, Elisaf MS: Lipoprotein (a) and acute-phase response in patients with vestibular neuronitis. Eur J Clin Invest 2003;33:1045–1050.
20.
Monaco C, Andreakos E, Young S, Feldmann M, Paleolog E: T cell-mediated signaling to vascular endothelium: induction of cytokines, chemokines, and tissue factor. J Leukoc Biol 2002;71:659–668.
21.
Muller WA, Weigl SA, Deng X, Phillips DM: Pecam-1 is required for transendothelial migration of leukocytes. J Exp Med 1993;178:449–460.
22.
Old LJ: Tumor necrosis factor (TNF). Science 1985;230:630–632.
23.
Omari KM, Dorovini-Zis K: CD40 expressed by human brain endothelial cells regulates CD4+ T cell adhesion to endothelium. J Neuroimmunol 2003;134:166–178.
24.
Patel T, Gores GJ, Kaufmann SH: The role of proteases during apoptosis. FASEB J 1996;10:587–597.
25.
Qing Z, Sandor M, Radvany Z, Sewell D, Falus A, Potthoff D, Muller WA, Fabry Z: Inhibition of antigen-specific T cell trafficking into the central nervous system via blocking pecam1/CD31 molecule. J Neuropathol Exp Neurol 2001;60:798–807.
26.
Shu U, Kiniwa M, Wu CY, Maliszewski C, Vezzio N, Hakimi J, Gately M, Delespesse G: Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur J Immunol 1995;25:1125–1128.
27.
Strupp M, Zingler VC, Arbusow V, Niklas D, Maag KP, Dieterich M, Bense S, Theil D, Jahn K, Brandt T: Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med 2004;351:354–361.
28.
Tewari M, Quan LT, O’Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM: Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995;81:801–809.
29.
Thienel U, Loike J, Yellin MJ: CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets. Cell Immunol 1999;198:87–95.
30.
Tracey KJ, Cerami A: Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994;45:491–503.
31.
Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S: CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 2002;106:981–986.
32.
van Kooten C, Gaillard C, Galizzi JP, Hermann P, Fossiez F, Banchereau J, Blanchard D: B cells regulate expression of CD40 ligand on activated T cells by lowering the mRNA level and through the release of soluble CD40. Eur J Immunol 1994;24:787–792.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.